Menu

Presentations + Publications

Alosa Health Presentations

  1. Primary Prevention of CVD: Reeves, S. Guest Lecture for National Medical Assistant Conference. May 13, 2023.
  2. Preventing Opioid Misuse and Enhancing Care: Trombetta, D. Guest Lecture for Delaware Pharmacists Society. May 12, 2023.
  3. Caring for Older Adults with Depression: Reeves, S. Guest Lecture for Pennsylvania Society of Medical Assistants. March 25, 2023.
  4. Managing Depression in Older Adults: Trombetta D, Fanikos P. Guest Lecture for New England Case Management Society. May 11, 2021.
  5. Pharmaco-epidemiology, Pharmaco-economics, and changing prescribing behavior. Jerry Avorn, lecture to Harvard-MIT Program in Health Science Technology, 2021.
  6. Academic Detailing and Opioid Prescribing. Frank K, Trombetta D. Guest Lecture for Wilkes University Pain Summit. April 23, 2021.
  7. The Theory and Evidence Behind Academic Detailing Programs.  Jerry Avorn, lecture to Harvard Medical School students, October 2021.
  8. Academic Detailing in Practice: Alosa and NaRCAD. Avorn J, Fanikos P, Dancel E. Guest Lecture for Harvard Medical School, Medications & Evidence Course. October 15, 2021.
  9. AD of Type 2 Diabetes in the ACO, FQHC, and the Public Payor Environment – panel. Fischer M, Fanikos P, Dancel E, Whitney D, Trombetta D. 8th International Conference on Academic Detailing. Virtual (Zoom). November 2020.
  10. The Theory and Evidence Behind Academic Detailing Programs.  Jerry Avorn, lecture to Harvard Medical School students, May, 2020.
  11. Academic Detailing in Practice. Fanikos P, Dancel E, Baines S. Guest Lecture for Harvard Medical School, Medications & Evidence Course. May 21, 2020.
  12. Managing chronic pain in the elderly. Bains S. Guest lecture for Abington Family Medicine. January 8, 2020.
  13. Pharmaco-epidemiology, Pharmaco-economics, and changing prescribing behavior. Jerry Avorn, lecture to Harvard-MIT Programs in Health Science Technology, 2020.
  14. Academic Detailing and the State Opioid Response. Fanikos P. Guest Lecture Louisiana Department of Health. December 4, 2019.
  15. Campaign materials & messaging: Creating tools for impact – workshop. Dancel E, Dumont Z. 7th International Conference on Academic Detailing. Boston MA. November 2019.
  16. Academic Detailing in Practice. Avorn J, Fanikos P. Guest Lecture BWH Division of Pharmacoepidemiology and Pharmacoeconomics for Keio University Program. July 19,2019.
  17. Substance Use Disorder: Prevention, Recognition, Response and Challenges – panel. Fanikos P, Nichols J, Peckham A, Kulhawik E. Northeastern University. June 20, 2019.
  18. Pharmaco-epidemiology, Pharmaco-economics, and changing prescribing behavior. Jerry Avorn, lecture to Harvard-MIT Program in Health Science Technology, 2019.
  19. Academic Detailing in Practice. Fanikos P. Guest Lecture for Shelby County TN Department of Health. May 2019.
  20. Managing chronic pain in the elderly. Reeves S. Guest speaker on WHTM News. February 18, 2019.
  21. Academic Detailing and Acute Pain Management. Garcia J. Guest lecture for University of Pittsburgh Medical Center at Harmot. September 20, 2018.
  22. Pharmaco-epidemiology, Pharmaco-economics, and changing prescribing behavior. Jerry Avorn, lecture to Harvard-MIT Program in Health Science Technology, 2018.
  23. Academic Detailing in Practice. Avorn J, Fanikos P. Guest Lecture BWH Division of Pharmacoepidemiology and Pharmacoeconomics for Keio University Program. July 24, 2018.
  24. Academic Detailing in Practice for STI Prevention. Luo J, Edelberg R, Fanikos P. Guest Lecture for CDC Division of STD. March 22, 2018.
  25. Managing chronic pain in the elderly. Reeves S. Guest lecture for the Opioid Task Force of Cumberland and Perry Counties. January 19, 2018.
  26. Creating Engaging Educational Materials: Visually Supporting Your Key Messages – workshop. Dancel E, Braddock A. 5th International Conference on Academic Detailing. Boston, MA. November 2017.
  27. Home care services for patients with Heart Failure. Bains S. Guest lecture at the PT/OT symposium on heart failure. October 14, 2017.
  28. Overcoming Opioids: Easing an epidemic 1 doctor at a time. Johnson C, Jones M. Article in the Associated Press based on the work of Melissa Jones. June 15, 2017. Received from https://apnews.com/article/health-north-america-us-news-ap-top-news-pennsylvania-38653b1ac256454485852e3c081c9b73
  29. Academic Detailing and Medication Safety. Fanikos P, Guest Lecture for South Carolina Pharmacist Association. April 24, 2017.
  30. Pharmaco-epidemiology, Pharmaco-economics, and changing prescribing behavior. Jerry Avorn, lecture to Harvard-MIT Program in Health Science Technology, 2017.
  31. Academic Detailing and non-biased education. Trombetta D. Guest lecture for Pocono Medical Center. April 11, 2017.
  32. Wellness Week at Lehigh Valley Health Network. Trombetta D. April 7, 2017.
  33. Academic Detailing in Practice. Fanikos P, Guest Lecture for City of Baltimore Department of Health. April 3, 2017.
  34. Heart Failure and other current modules. Jones M. PowerPoint presentation for Premier Medical Associates. Monroeville, PA. March 13, 2016.

Published Alosa Health articles

  1. Solomon DH, Avorn J, Levin R, Brookhart MA.  Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis. 2008;  67: 609-13.
  2. Brookhart MA, Avorn J, Polinksi JM, Brown TV, Mogun H, Solomon DH.  The medical license number accurately identifies the prescribing physician in a large pharmacy claims database. Med Care. 2007; 45:907-10.
  3. Solomon DH, Katz JN, Finkelstein JS, Polinski JM, Stedman M, Brookhart MA, Arnold M, Gauthier S, Avorn J.  Osteoporosis improvement: a large-scale randomized controlled trial of patient and primary care physician education. J Bone Miner Res. 2007; 22:1808-15.
  4. van Wijk BL, Shrank WH, Klungel OH, Schneeweiss S, Brookhart MA, Avorn J.  A cross-national study of the persistence of antihypertensive medication use in the elderly. J Hypertens. 2008; 26:145-53.
  5. Rassen JA, Choudhry NK, Avorn J, Schneeweiss S. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation. 2009  Dec 8;120(23):2322-9.
  6. Avorn J, Schneeweiss S. Managing drug-risk information–what to do with all those new numbers. N Engl J Med. 2009 Aug 13;361(7):647-9.  7.
  7. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009 Jul;20(4):512-22.
  8. Shrank WH, Choudhry NK, Solomon DH, Snedden TM, Lee TH, Glynn RJ, Brown TV, Jolda C, Spetman M, Brookhart MA, Schneeweiss S, Avorn J. Rationale and design of the Study Assessing the Effect of Cardiovascular Medications Provided as Low-cost, Evidence-based Generic Samples (SAMPLES) trial. Am Heart J. 2009 Apr;157(4):613-9.
  9. Avorn J, Choudhry NK. Funding for medical education: maintaining a healthy separation from industry. Circulation. 2010 May 25;121(20):2228-34.
  10. Avorn J. Transforming trial results into practice change: the final translational hurdle: Comment on “Impact of the ALLHAT/JNC7 Dissemination Project on thiazide-type diuretic use”. Arch Intern Med. 2010 May 24;170(10):858-60.
  11. Solomon DH, Gleeson T, Iversen M, Avorn J, Brookhart MA, Lii J, Losina E, May F, Patrick A, Shrank WH, Katz JN. A blinded randomized controlled trial of motivational interviewing to improve adherence with osteoporosis medications: design of the OPTIMA trial. Osteoporos Int. 2010 Jan;21(1):137-44
  12. Avorn J. Medication use in older patients: better policy could encourage better practice. JAMA. 2010 Oct 13;304(14):1606-7.
  13. Avorn J, Fischer M. ‘Bench to behavior’: translating comparative effectiveness research into improved clinical practice. Health Aff (Millwood). 2010 Oct;29(10):1891-900. PubMed PMID: 20921491.
  14. Rassen JA, Avorn J, Schneeweiss S. Multivariate-adjusted pharmacoepidemiologic analyses of confidential information pooled from multiple health care utilization databases. Pharmacoepidemiol Drug Saf. 2010 Aug;19(8):848-57.
  15. Avorn J. The relative cost-effectiveness of anticoagulants: obvious, except for the cost and the effectiveness. Circulation. 2011 Jun 7;123(22):2519-21. Epub 2011 May 23. PubMed PMID: 21606400.
  16. Avorn J. Teaching clinicians about drugs–50 years later, whose job is it? N Engl J Med. 2011 Mar 31;364(13):1185-7. PubMed PMID: 21449781.
  17. Fischer MA, Avorn J. Academic detailing can play a key role in assessing and implementing comparative effectiveness research findings. Health Aff (Millwood). 2012 Oct;31(10):2206-12. doi: 10.1377/hlthaff.2012.0817. PubMed PMID: 23048098.
  18. Avorn J. Two centuries of assessing drug risks. N Engl J Med. 2012 Jul 19;367(3):193-7. PubMed PMID: 22808954.
  19. Austad KE, Avorn J, Franklin JM, Kowal MK, Campbell EG, Kesselheim AS.
  20. Changing Interactions Between Physician Trainees and the Pharmaceutical Industry: A National Survey. J Gen Intern Med. 2013 Feb 27. [Epub ahead of print] PubMed PMID: 23444007.
  21. Kesselheim AS, Mello MM, Avorn J. FDA regulation of off-label drug promotion under attack. JAMA. 2013 Feb 6;309(5):445-6. doi: 10.1001/jama.2012.207972. PubMed PMID: 23385267.
  22. Avorn J. Healing the overwhelmed physician. [op-ed] New York Times, June 11, 2013.
  23. Kesselheim AS, Bykov K, Avorn J, Tong A, Doherty M, Choudhry NK. Burden of changes in pill appearance for patients receiving generic cardiovascular medications after myocardial infarction: cohort and nested case-control studies. Ann Intern Med. 2014 Jul 15;161(2):96-103. doi: 10.7326/M13-2381. PubMed PMID:25023248.
  24. Avorn J. Rethinking the use of physicians as hired expert lecturers. Ann Intern Med. 2014 Sep 2;161(5):363-4. doi: 10.7326/M14-0847. PubMed PMID: 25178570.
  25. Gagne JJ, Choudhry NK, Kesselheim AS, Polinski JM, Hutchins D, Matlin OS, Brennan TA, Avorn J, Shrank WH. Comparative effectiveness of generic and brand-name statins on patient outcomes: a cohort study. Ann Intern Med. 2014 Sep 16;161(6):400-7. doi: 10.7326/M13-2942. PubMed PMID: 25222387.
  26. Avorn J. The $2.6 billion pill–methodologic and policy considerations. N Engl J Med. 2015 May 14;372(20):1877-9. doi: 10.1056/NEJMp1500848. PubMed PMID: 25970049.
  27. Avorn J, Sarpatwari A, Kesselheim AS. Forbidden and Permitted Statements about Medications–Loosening the Rules. N Engl J Med. 2015 Sep 3;373(10):967-73. doi: 10.1056/NEJMhle1506365. PubMed PMID: 26332553.
  28. Kesselheim AS, Avorn J, Sarpatwari A. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform. JAMA. 2016 Aug 23-30;316(8):858-71. doi: 10.1001/jama.2016.11237. Review. PubMed PMID: 27552619.
  29. Huybrechts KF, Desai RJ, Park M, Gagne JJ, Najafzadeh M, Avorn J. The Potential Return on Public Investment in Detecting Adverse Drug Effects. Med Care. 2017 Jun;55(6):545-551. doi: 10.1097/MLR.0000000000000717. PubMed PMID: 28505041; PubMed Central PMCID: PMC5433260.
  30. Kesselheim AS, Donneyong M, Dal Pan GJ, Zhou EH, Avorn J, Schneeweiss S, Seeger JD. Changes in prescribing and healthcare resource utilization after FDA Drug Safety Communications involving zolpidem-containing medications. Pharmacoepidemiol Drug Saf. 2017 Jun;26(6):712-721. doi: 10.1002/pds.4215. Epub 2017 Apr 27. PubMed PMID: 28449404.
  31. Kesselheim AS, McGraw SA, Dejene SZ, Rausch P, Dal Pan GJ, Lappin BM, Zhou EH, Avorn J, Campbell EG. Patient and Physician Perceptions of Drug Safety Information for Sleep Aids: A Qualitative Study. Drug Saf. 2017 Jun;40(6):531-542. doi: 10.1007/s40264-017-0516-3. PubMed PMID: 28247279.
  32. Trotter Davis M, Bateman B, Avorn J. Educational Outreach to Opioid Prescribers: The Case for Academic Detailing. Pain Physician. 2017 Feb;20(2S):S147-S151. PubMed PMID: 28226336.
  33. Fralick M, Kesselheim A, Avorn J. Applying Academic Detailing and Process Change to Promote Choosing Wisely. JAMA Intern Med. 2017 Feb 1;177(2):282. doi: 10.1001/jamainternmed.2016.8503. PubMed PMID: 28166340.
  34. Fischer MA, Avorn J. Step Therapy-Clinical Algorithms, Legislation, and Optimal Prescribing. JAMA. 2017 Feb 28;317(8):801-802. doi: 10.1001/jama.2016.20619. PubMed PMID: 28166322.
  35. Avorn J. Academic Detailing: “Marketing” the Best Evidence to Clinicians. JAMA. 2017 Jan 24;317(4):361-362. doi: 10.1001/jama.2016.16036. PubMed PMID: 28118458.
  36. Avorn J, Kesselheim A, Sarpatwari A. The FDA Amendments Act of 2007 – Assessing Its Effects a Decade Later. N Engl J Med. 2018 Sep 20;379(12):1097-1099. doi: 10.1056/NEJMp1803910. PubMed PMID: 30231220.
  37. Sacks CA, Lee CC, Kesselheim AS, Avorn J. Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents. JAMA. 2018 Aug 21;320(7):650-656. doi: 10.1001/jama.2018.11439. PubMed PMID: 30140875; PubMed Central PMCID: PMC6142946.
  38. Sarpatwari A, Avorn J, Kesselheim AS. An Incomplete Prescription: President Trump’s Plan to Address High Drug Prices. JAMA. 2018 Jun 19;319(23):2373-2374. doi: 10.1001/jama.2018.7424. PubMed PMID: 29800027.
  39. Avorn J. The Psychology of Clinical Decision Making – Implications for Medication Use. N Engl J Med. 2018 Feb 22;378(8):689-691. doi: 10.1056/NEJMp1714987. PubMed PMID: 29466158.
  40. Feldman WB, Avorn J, Kesselheim AS. Potential Medicare Savings on Inhaler Prescriptions Through the Use of Negotiated Prices and a Defined Formulary. JAMA Intern Med. 2019 Dec 2. doi: 10.1001/jamainternmed.2019.5337. [Epub ahead of print] PubMed PMID: 31790541.
  41. Fischer MA, Kesselheim AS, Lu Z, Ross KM, Tessema FA, Avorn J. Physician Perceptions of Step Therapy Prescribing Requirements. J Manag Care Spec Pharm.2019 Nov;25(11):1210-1224. doi: 10.18553/jmcp.2019.25.11.1210. PubMed PMID:31663459.
  42. Growdon ME, Sacks CA, Kesselheim AS, Avorn J. Potential Medicare Savings From Generic Substitution and Therapeutic Interchange of ACE Inhibitors and Angiotensin-II-Receptor Blockers. JAMA Intern Med. 2019 Aug 5. doi: 10.1001/jamainternmed.2019.3107. [Epub ahead of print] PubMed PMID: 31380893; PubMed Central PMCID: PMC6686978.
  43. Kesselheim AS, Sinha MS, Campbell EG, Schneeweiss S, Rausch P, Lappin BM, Zhou EH, Avorn J, Dal Pan GJ. Multimodal Analysis of FDA Drug Safety Communications: Lessons from Zolpidem. Drug Saf. 2019 Nov;42(11):1287-1295. doi:10.1007/s40264-019-00849-8. PubMed PMID: 31302895.
  44. Darrow J, Avorn J, Kesselheim AS. FDA Regulation and Approval of Pharmaceuticals, 1983-2018. JAMA 2020. Jan 14;323(2):164-176. doi: 10.1001/jama.2019.20288. Erratum in: JAMA. 2020 Feb 11;323(6):573. PMID: 31935033.
  45. Feldman WB, Avorn J, Kesselheim AS. Potential Medicare Savings on Inhaler Prescriptions Through the Use of Negotiated Prices and a Defined Formulary. JAMA Intern Med. 2020 Mar 1;180(3):454-456. doi: 10.1001/jamainternmed.2019.5337. PMID: 31790541; PMCID: PMC6902106.
  46. Kesselheim AS, Hwang TJ, Avorn J. Paying for prescription drugs in the new administration. JAMA 2021.
  47. Kesselheim AS, Darrow JJ, Kulldorff M, Brown BL, Mitra-Majumdar M, Lee CC, Moneer O, Avorn J. An Overview Of Vaccine Development, Approval, And Regulation, With Implications For COVID-19. Health Aff (Millwood). 2021 Jan;40(1):25-32. doi: 1377/hlthaff.2020.01620. Epub 2020 Nov 19. PMID: 33211535.
  48. Rome BN, Feldman WB, Fischer MA, Desai RJ, Avorn J. Influenza Vaccine Uptake in the Year After Concurrent vs Separate Influenza and Zoster Immunization. JAMA Netw Open. 2021 Nov 1;4(11):e2135362. doi: 10.1001/jamanetworkopen.2021.35362. PMID: 34797367
  49. Bendicksen L, Rome BN, Avorn J, Kesselheim AS. Pursuing Value-Based Prices for Drugs: A Comprehensive Comparison of State Prescription Drug-Pricing Boards. Milbank Q. 2021 Dec;99(4):1162-1197. doi: 10.1111/1468-0009.12533. Epub 2021 Aug 10. PMID: 34375015
  50. Sarpatwari A, Mitra-Majumdar M, Bykov K, Avorn J, Woloshin S, Toyserkani GA, LaCivita C, Manzo C, Zhou EH, Pinnow E, Dal Pan GJ, Gagne JJ, Huybrechts KF, Feldman WB, Chin K, Kesselheim AS.A Multi-modal Approach to Evaluate the Impact of Risk Evaluation and Mitigation Strategy (REMS) Programs.
  51. Drug Saf. 2021 Jul;44(7):743-751. doi: 10.1007/s40264-021-01070-2. Epub 2021 Apr 27. PMID: 33904111
  52. Feldman WB, Rome BN, Avorn J, Kesselheim AS. The Future of Drug-Pricing Transparency. N Engl J Med. 2021 Feb 11;384(6):489-491. doi: 10.1056/NEJMp2033734. Epub 2021 Jan 13. PMID: 33440087
  53. Rome BN, Gagne JJ, Avorn J, Kesselheim AS. Non-warfarin oral anticoagulant copayments and adherence in atrial fibrillation: A population-based cohort study. Am Heart J. 2021 Mar;233:109-121. doi: 10.1016/j.ahj.2020.12.010. Epub 2021 Jan 14. PMID: 33358690
  54. Kesselheim AS, Avorn J. Opinion: The FDA has reached a new low: Its approval of the Alzheimer’s drug aducancumab is inexplicable. The New York Times, June 16, 2021
  55. Lee CC, Kesselheim AS, Avorn J. Variations in Generic Combination Opioid Use Across State Medicaid Programs.  J Gen Intern Med. 2021 Oct;36(10):3240-3242. doi: 10.1007/s11606-020-06315-x. Epub 2020 Nov 2. PMID: 33140274.
  56. Kesselheim AS, Avorn J. Outlook: Letting the government negotiate drug prices won’t hurt innovation. The Washington Post, Sept. 22, 2021.
BALANCED INFORMATION FOR BETTER CARE

Alosa Health

20 Park Plaza, Suite 821
Boston, MA 02116

info@alosahealth.org

(617) 948-5997

Click to receive Alosa updates

© Copyright 2024 Alosa Health